Wegovy GoodRx vs Savings Card: Which Is Cheaper in 2026?

Wegovy GoodRx vs the savings card: the short answer

A GoodRx coupon and the Novo Nordisk savings card are not competing offers for the same person. They apply in different situations, and a pharmacy runs only one of them per fill.

If your commercial plan covers Wegovy for chronic weight management, the savings card gets you to the lowest number: Novo Nordisk lists that floor at as little as $25 per month, checked on wegovy.com on 17 August 2026. If you're paying cash, the comparison shifts. The real contest is between a GoodRx retail coupon and Novo's own NovoCare direct-ship pharmacy, and on the figures available the direct-ship channel is substantially cheaper for the pen.

One caveat carries through the whole article. GoodRx sets prices per pharmacy and per ZIP code, and the GoodRx figures here come from a snapshot dated around May 2026, not a check performed today. Use them to read the shape of the market, then pull a live quote on goodrx.com for your own dose and location. The savings-card, NovoCare, and Medicare figures were each checked against their program's official page on 17 August 2026.

Three programs, three eligibility gates. Figures as dated below.

How the Wegovy savings card works

Eligibility and the $25 per month floor

The Novo Nordisk savings card is a copay reduction, not a standalone discount. It attaches to a commercial insurance claim that has already been approved for Wegovy, and it lowers what you hand over at the counter. Novo Nordisk states the resulting cost can be as little as $25 per month for patients whose commercial plan covers the drug, per wegovy.com as checked on 17 August 2026. Prior authorization is a common precondition set by the insurer rather than by Novo, and the card cannot substitute for one.

The $100 savings cap, and why $25 is a floor rather than a price

This is the detail most coupon comparisons skip. The card is capped in how much it will contribute: up to $100 on a 1-month fill, $200 on a 2-month fill, and $300 on a 3-month fill, per the card's own tiering as published on wegovy.com on 17 August 2026. It also will not reduce your cost below $25, even when the full $100 is not needed. So the rule for a one-month fill is your copay minus $100, or $25, whichever is higher.

Run it both ways. At a $180 copay the card contributes its $100 maximum and you pay $80, not $25. At a $110 copay the subtraction gives $10, but the floor holds and you pay $25. Only a copay above $125 puts you above $25.

So if you're insured, the question isn't whether the card exists. It's what your plan's copay actually is. Call your insurer, ask for the Wegovy copay on your tier, subtract $100, and take $25 if the result comes in lower. That number is what you compare against a GoodRx quote.

Who the card excludes

Beneficiaries of government-funded coverage, including Medicare, Medicaid, and TRICARE, are excluded from the manufacturer card by its own terms. That's a standing feature of manufacturer copay programs across the industry, and pharmacies cannot override it at the counter. If you're in that group, skip to the Medicare and TRICARE section below rather than trying to make the card work.

Wegovy GoodRx pricing at major pharmacies

What the coupon has been running

In a per-pharmacy price table dated around May 2026, GoodRx coupon prices for the Wegovy injectable pen ran from roughly $1,229 at the low end (a warehouse-club pharmacy) to roughly $1,419 at the high end (large chain pharmacies). Treat that as a dated snapshot rather than today's quote.

For context on the undiscounted end of the scale, Wegovy's cash list price has been reported in the range of roughly $1,350 to $1,865 per month depending on the pharmacy, on pricing data from May 2026. A GoodRx coupon in the $1,200s does represent a real reduction against that. The problem is what it is being compared against, which the next section covers.

GoodRx Care Direct is a different channel from the coupon

GoodRx also operates a telehealth service, separate from the coupon product, that dispenses the oral semaglutide tablet rather than the injectable pen. Any price attached to it is a tablet price, so it is not comparable to a pen price. We could not verify that service's current pricing or fee structure against a primary source, so no figure for it appears here. If the tablet is what you are prescribed, check the program's own page.

Why a coupon cannot be stacked on insurance

A pharmacy processes one payment pathway per fill. Either the claim goes through your insurance, with the savings card applied on top of the adjudicated copay, or the fill is processed as a cash transaction with the GoodRx coupon price. A pharmacy cannot apply both to one fill. So price both routes separately and pick the lower one, and note that a GoodRx coupon stays available as a fallback if your plan denies coverage outright.

NovoCare direct-ship self-pay pricing

Current self-pay tiers by dose

NovoCare Pharmacy is Novo Nordisk's own cash-pay, direct-ship channel. It does not process insurance, and the savings card does not apply to it. The tiers below were read directly from novocare.com on 17 August 2026 and apply to self-pay patients with a valid Wegovy prescription.

The pen, head to head

Set the two self-pay options side by side on a 1mg, 1.7mg or 2.4mg maintenance pen. NovoCare direct-ship is $349 per month as of 17 August 2026. The GoodRx coupon range from the May 2026 snapshot sits at roughly $1,229 to $1,419. On those two data points, direct-ship is in the region of three and a half to four times cheaper for the same product.

The reason is structural, not promotional. A GoodRx coupon reduces what a retail pharmacy charges, and that price still carries the pharmacy's acquisition cost and margin. NovoCare ships from the manufacturer's own pharmacy, so the retail layer isn't in the chain. If you're paying cash for the pen, price NovoCare first and use GoodRx as the comparison rather than the default.

Which eligibility class you are actually in

Which of these four situations describes you settles the question.

• Commercial insurance, plan covers Wegovy. Use the savings card. Ask your insurer for your actual Wegovy copay, subtract $100 for a 1-month fill, take $25 if the result comes in lower, and compare that against a live GoodRx quote. In this class the card usually wins comfortably.
• Commercial insurance, plan excludes Wegovy or prior authorization was denied. The card is built to run on top of an approved commercial claim, so with no approved claim there's nothing for it to reduce. You're pricing as a cash payer: compare NovoCare's tiers against a live GoodRx quote.
• Medicare, Medicaid, or TRICARE. The manufacturer card is unavailable to you under its terms. On Part D, check three routes in this order: your plan's formulary under Wegovy's cardiovascular indication, then the CMS Medicare GLP-1 Bridge, then cash pay. Formulary first, because already receiving a GLP-1 covered by your plan rules you out of the Bridge.
• Uninsured or paying cash by choice. Start with NovoCare's published tiers, then check GoodRx for your ZIP code as a comparison. On the figures in this article, NovoCare is the cheaper route for the pen.

Four eligibility classes, four different answers.

Medicare, Medicaid, and TRICARE

Medicare Part D and the obesity exclusion

Medicare Part D has long excluded drugs used for weight loss from its standard covered-drug definition under the Social Security Act, carried through in the CMS Prescription Drug Benefit Manual. Wegovy prescribed for chronic weight management falls inside that exclusion.

The exclusion is tied to the indication, not the drug, and that distinction matters. Wegovy's current label carries a cardiovascular indication: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, conventionally a BMI of 27 or above. In a March 2024 memorandum to Part D sponsors, CMS said an anti-obesity medication that gains an additional medically accepted indication can be considered a Part D drug for that specific use, and that sponsors may apply prior authorization to confirm it. So a plan may list Wegovy and still require prior authorization. Covering it is permitted rather than required, so whether yours does is a formulary question. The savings card stays closed to Part D beneficiaries either way.

Keep the mechanisms separate. The Bridge is a CMS coverage pathway with its own eligibility gate. It does not open the savings card to government beneficiaries, it is not a discount on the NovoCare or GoodRx prices above, and it is distinct from Part D formulary coverage under the cardiovascular indication. The two do not stack: if you are already receiving a GLP-1 covered by your plan, the Bridge rules you out. Check your formulary first, then the Bridge.

Medicaid and TRICARE

Medicaid coverage of weight-management drugs is set state by state, so whether Wegovy is on your state's preferred drug list is a question for your state Medicaid program.

TRICARE needs two separate questions kept apart. As a manufacturer program, the savings card excludes TRICARE beneficiaries along with other government-funded coverage. Whether TRICARE itself pays for Wegovy is a different matter: coverage varies by plan and commonly requires prior authorization tied to a documented weight-related diagnosis. Check with your TRICARE regional contractor for your plan's current policy rather than assuming either outcome.